These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. IL-10 cooperates with TNF-alpha to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage. Finnegan A; Roebuck KA; Nakai BE; Gu DS; Rabbi MF; Song S; Landay AL J Immunol; 1996 Jan; 156(2):841-51. PubMed ID: 8543841 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 and glucocorticoids synergistically induce human immunodeficiency virus type-1 expression in chronically infected U1 cells by a long terminal repeat independent post-transcriptional mechanism. Kinter AL; Biswas P; Alfano M; Justement JS; Mantelli B; Rizzi C; Gatti AR; Vicenzi E; Bressler P; Poli G Mol Med; 2001 Oct; 7(10):668-78. PubMed ID: 11713366 [TBL] [Abstract][Full Text] [Related]
12. Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Poli G; Kinter AL; Fauci AS Proc Natl Acad Sci U S A; 1994 Jan; 91(1):108-12. PubMed ID: 7506410 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-10 enhances human immunodeficiency virus type 1 expression in a chronically infected promonocytic cell line (U1) by a tumor necrosis factor alpha-independent mechanism. Angel JB; Saget BM; Wang MZ; Wang A; Dinarello CA; Skolnik PR J Interferon Cytokine Res; 1995 Jun; 15(6):575-84. PubMed ID: 7553227 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-8 fails to induce human immunodeficiency virus-1 expression in chronically infected promonocytic U1 cells but differentially modulates induction by proinflammatory cytokines. Tiemessen CT; Kilroe B; Martin DJ Immunology; 2000 Sep; 101(1):140-6. PubMed ID: 11012765 [TBL] [Abstract][Full Text] [Related]
15. Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous kappa-opioid receptor agonist. Hiramatsu M; Murasawa H; Mori H; Kameyama T Br J Pharmacol; 1998 Mar; 123(5):920-6. PubMed ID: 9535021 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. Kong LY; McMillian MK; Hudson PM; Jin L; Hong JS J Pharmacol Exp Ther; 1997 Jan; 280(1):61-6. PubMed ID: 8996182 [TBL] [Abstract][Full Text] [Related]
17. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779 [TBL] [Abstract][Full Text] [Related]
18. IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage. Weissman D; Poli G; Fauci AS J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Aug; 9(5):442-9. PubMed ID: 7627621 [TBL] [Abstract][Full Text] [Related]
19. Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation. Li JG; Zhang F; Jin XL; Liu-Chen LY J Pharmacol Exp Ther; 2003 May; 305(2):531-40. PubMed ID: 12606694 [TBL] [Abstract][Full Text] [Related]
20. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum. Schoffelmeer AN; Hogenboom F; Mulder AH Br J Pharmacol; 1997 Oct; 122(3):520-4. PubMed ID: 9351509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]